The EU Health Technology Assessment Regulation (EU HTAR) and Joint Clinical Assessment (JCA) aim to harmonize clinical evaluations across Europe while preserving national HTA decisions. To navigate this complexity, early and strategic PICO (Population, Intervention, Comparator, Outcome) planning is essential for effective evidence generation strategies.
This study, presented at ISPOR Europe 2025, demonstrates how NAVLIN by EVERSANA’s validated PICO Planner combines targeted literature reviews, HTA reports, clinical guidelines, and reimbursement insights to accurately predict PICOs for upcoming EU HTA requirements.
It also highlights how this structured, data-driven methodology streamlines evidence planning, improves alignment with HTA expectations, and supports better trial design and strategic decision-making.
Download the full poster now to discover how EVERSANA’s PICO planner can streamline your EU HTA strategy.
Author
Shivani Shah is Senior Consultant at EVERSANA and has around 6 years of experience working as consultant in pharmaceutical and life-science industry. Prior to joining EVERSANA, she has worked at one of the top…
As a Director of Global Market Access and Pricing, Richard leads global consulting engagements within EVERSANA. Richard comes with 13+ year of Life Sciences Consulting and Industry experience. He supported 40+ pharma brands preparing…
Alan has spent close to 20 years doing commercial work for the life sciences industry. His experience includes creating innovative solutions for global pricing and access, including work on price optimization, global data collection…